In 2013, Mumcu et al. [33] showed that salivary and serum BAFF levels were lowered in patients with pSS when treated with HCQ, and also that decreased disease activity and increased salivary flow could be achieved using HCQ treatment in pSS patients. The gene discussed is TNFSF13B; the disease is peeling skin syndrome.